Published on: 30-04-2020
To limit patient exposure to the virus, a direct-to-patient approach is the best way to maintain an effective therapeutic strategy.
The COVID-19 crisis is significantly hindering clinical research, putting the lives of patients with unmet medical needs at risk. To limit patient exposure to the virus, a direct-to-patient approach is the best way to maintain an effective therapeutic strategy.
The direct-to-patient design allows the dispatch of treatments directly to patients’ homes. Trial medication can thus be administered on time and under optimal conditions for stability.
This design also secures the handling and shipment of biological sample towards central or local laboratories.
At 4Clinics, our decentralized nursing network provides wide geographical coverage bringing medical care straight to patients’ homes. Our GCP trained nurses ensure correct administration of treatments, administration of clinical tests and management of biological samples.
4Clinics services support direct-to-patient trials either from the ground up or following amendment of an ongoing study:
– Patient reported outcomes can be collected using our remote applications handled by our in-house data management group
– Our nursing network reduces the need for on-site visits
– Logistics for both treatment and sample shipment through our partnerships with expert logisticians
4Clinics is a Clinical Research Organization providing Data management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical, observational and epidemiological studies with offices in Belgium, France, Morocco, USA and Canada and a global coverage.
Mehdi CHELBI – Director Business Development
Alexandre FAYEL – Business Development Manager